

**TSH BIOPHARM CORPORATION LTD.  
AND SUBSIDIARIES  
CONSOLIDATED FINANCIAL STATEMENTS  
AND INDEPENDENT AUDITORS' REVIEW REPORT  
FOR THE NINE MONTHS ENDED  
SEPTEMBER 30, 2025 AND 2024**

**Address : 3F.-1, No. 3-1, Park St., Nangang Dist., Taipei City 115, Taiwan (R.O.C.)**

**Telephone No. : 02-26558525**

-----  
For the convenience of readers and for information purpose only, the independent auditors' report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' report and financial statements shall prevail.

## Table of contents

Contents	Page
1.Cover Page	1
2.Table of Contents	2
3.Independent Auditors’ Review Report	3~4
4.Consolidated Balance Sheets	5
5.Consolidated Statements of Comprehensive Income	6
6.Consolidated Statements of Changes in Equity	7
7.Consolidated Statements of Cash Flows	8~9
8.Notes to the Consolidated Financial Statements	10
(1) History and organization	10
(2) Approval date and procedures of the financial statements	10
(3) Application of new standards, amendments and interpretations	10~11
(4) Summary of significant accounting policies	12~13
(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty	13
(6) Explanation of significant accounts	13~38
(7) Related-party transactions	38~40
(8) Pledged assets	40
(9) Significant commitments and contingencies	40
(10) Losses due to major disasters	40
(11) Significant subsequent events	40
(12) Other	41
(13) Other disclosures	41
A. Information on significant transactions	41~42
B. Information on investees	43
C. Information on investment in mainland China	43
(14) Segment information	43~44

## INDEPENDENT AUDITORS' REVIEW REPORT

To the Board of Directors of TSH Biopharm Corporation Ltd.

### Introduction

We have reviewed the accompanying consolidated balance sheets of TSH Biopharm Corporation Ltd. and its subsidiaries (the “Group”) as of September 30, 2025 and 2024, and the related consolidated statements of comprehensive income, changes in equity and cash flows for the three months and nine months ended September 30, 2025 and 2024, and notes to the consolidated financial statements, including a summary of significant accounting policies. Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the “Regulations Governing the Preparation of Financial Reports by Securities Issuers” and International Accounting Standard (IAS) No.34, “Interim Financial Reporting” as endorsed by the Financial Supervisory Commission (FSC) of the Republic of China. Our responsibility is to express a conclusion on these interim the financial statements based on our reviews.

### Scope of Review

We conducted our reviews in accordance with the Standard on Review Engagements 2410, “Review of Financial Information Performed by the Independent Auditor of the Entity”. A review of consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing of the Republic of China and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### Conclusion

Based on our reviews, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of the Group as of September 30, 2025 and 2024, and of its consolidated financial performance and its cash flows for the three months and nine months ended September 30, 2025 and 2024, in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting” endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

KPMG

Taipei, Taiwan (Republic of China)

November 5, 2025

---

The accompanying consolidated financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying consolidated financial statements and report of independent accountants are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

(English Translation of the Consolidated Financial Statements Originally Issued in Chinese)  
**TSH Biopharm Corporation Ltd. and Subsidiaries**  
**Consolidated Balance Sheets**  
**September 30, 2025, December 31, 2024 and September 30, 2024**  
**(Expressed in thousands of New Taiwan Dollars)**

Assets	30-Sep-25		31-Dec-24		30-Sep-24		Liabilities and Equity	30-Sep-25		31-Dec-24		30-Sep-24	
	Amount	%	Amount	%	Amount	%		Amount	%	Amount	%	Amount	%
<b>Current assets:</b>							<b>Current liabilities:</b>						
1100 Cash and cash equivalents (notes 6(1) 、(5) and (20))	\$ 588,644	29	588,342	32	585,106	31	2130 Contract liabilities-current (note 6(17))	\$ 1,864	-	1,039	-	3,436	-
1120 Current financial assets at fair value through other comprehensive income (notes 6(2) 、(20) and 13)	88,876	5	77,015	4	98,307	5	2150 Notes payable (notes 6(5) 、(20))	11,890	1	16,532	1	13,275	1
1150 Notes receivable, net (notes 6(3) 、(5) 、(17) and (20))	11,173	1	11,023	1	11,363	-	2170 Accounts payable (notes 6(5) 、(20))	20,436	1	18,057	1	17,968	1
1170 Accounts receivable, net (notes 6(3) 、(5) 、(17) and (20))	346,672	17	199,483	11	316,934	17	2180 Accounts payable to related parties (notes 6(20) and 7)	144,510	7	36,766	2	115,932	6
1180 Accounts receivable from related parties (notes 6(3) 、(17) 、(20) and 7)	1,138	-	1,177	-	3,534	-	2200 Other payables (notes 6(11) 、(20) and 7)	95,954	5	90,708	5	88,353	5
1220 Current income tax assets	313	-	205	-	144	-	2230 Current income tax liabilities (note 6(5))	21,152	1	32,232	1	19,739	1
1200 Other receivables (note 6(20))	2,991	-	2,182	-	38,718	2	2280 Current lease liabilities (notes 6(5) 、(12) 、(20) 、(23) and 7)	10,836	1	10,101	-	7,453	-
130x Inventories (notes 6(4) 、(5))	192,455	10	176,075	10	172,607	9	2300 Other current liabilities (note 6(5))	3,096	-	3,460	-	2,406	-
1410 Prepayments	5,400	-	16,788	1	13,792	1		309,738	16	208,895	10	268,562	14
1476 Other financial assets-current (notes 6(1) 、(5) 、(10) 、(20) and 8)	237,000	12	232,000	13	127,000	7	<b>Non-current liabilities:</b>						
1479 Other current assets –other (note 6(10) )	2,151	-	412	-	1,274	-	2580 Non-current lease liabilities (notes 6(5) 、(12) 、(20) 、(23) and 7)	8,075	-	10,330	1	5,305	-
	1,476,813	74	1,304,702	72	1,368,779	72	<b>Total liabilities</b>	317,813	16	219,225	11	273,867	14
<b>Non-current assets:</b>							<b>Equity (note 6(15)) :</b>						
1517 Non-current financial assets at fair value through other comprehensive income (notes 6(2) 、(20) and 13)	190,329	9	186,213	10	183,009	10	3100 Capital stock	383,981	19	383,981	21	383,981	20
1600 Property, plant and equipment (notes 6(5) 、(7))	18,165	1	19,989	1	26,183	1	3200 Capital surplus	459,613	23	459,554	25	459,554	24
1755 Right-of-use assets (notes 6 (5) 、(8))	18,760	1	20,425	1	12,694	1	Retained earnings :						
1780 Intangible assets (notes 6 (5) 、(9))	292,094	14	287,652	16	294,505	16	3310 Legal reserve	158,200	7	126,073	7	126,073	7
1840 Deferred income tax assets	4,015	-	4,015	-	1,509	-	3350 Unappropriated retained earnings	356,485	18	354,605	19	344,996	18
1915 Prepayment for equipment	6,011	-	4,030	-	3,186	-	3400 Other equity	83,750	4	67,579	4	88,165	5
1920 Refundable deposits paid (notes 6(10) 、(20) and 7)	8,026	1	8,750	-	9,107	-	Equity attributable to owners of the parent company	1,442,029	71	1,391,792	76	1,402,769	74
1995 Other non-current assets (notes 6(5) 、(10) and 9)	4,994	-	6,417	-	6,417	-	36xx Non-controlling interest (notes 6(5) 、(6))	259,365	13	231,176	13	228,753	12
	542,394	26	537,491	28	536,610	28	<b>Total equity</b>	1,701,394	84	1,622,968	89	1,631,522	86
<b>Total assets</b>	<b>\$ 2,019,207</b>	<b>100</b>	<b>1,842,193</b>	<b>100</b>	<b>1,905,389</b>	<b>100</b>	<b>Total liabilities and equity</b>	<b>\$ 2,019,207</b>	<b>100</b>	<b>1,842,193</b>	<b>100</b>	<b>1,905,389</b>	<b>100</b>

See accompanying notes to financial statements.

(English Translation of the Consolidated Financial Statements Originally Issued in Chinese)  
**TSH Biopharm Corporation Ltd. and Subsidiaries**  
**Consolidated Statements of Comprehensive Income**  
**For the three months and nine months periods ended September 30, 2025 and 2024**  
(Expressed in Thousands of New Taiwan Dollars, Except for Earnings Per Share)

		Three months periods ended September 30				Nine months periods ended September 30			
		2025		2024		2025		2024	
		AMOUNT	%	AMOUNT	%	AMOUNT	%	AMOUNT	%
4000	Operating revenue (notes 6(17) and 7)	\$ 422,583	100	388,532	100	978,997	100	824,613	100
5000	Operating costs (notes 6(4) and 7)	220,439	52	200,212	52	477,652	49	387,434	47
	Gross profit	202,144	48	188,320	48	501,345	51	437,179	53
6000	Operating expenses (notes 6(3) 、(12) 、(13) 、 (18) 、7 and 12):								
6100	Selling expenses	85,779	19	79,614	19	227,102	23	172,941	21
6200	Administrative expenses	25,825	6	28,037	7	80,400	8	99,607	12
6300	Research and development expenses	4,643	1	5,987	2	16,776	2	21,050	2
6450	Expected credit losses (gain on reversal)	1,649	-	903	-	1,225	-	1,693	-
		117,896	26	114,541	28	325,503	33	295,291	35
	Operating income	84,248	22	73,779	20	175,842	18	141,888	18
	Non-operating income and expenses (notes 6(12) 、(19) and 7):								
7100	Interest income	1,243	-	542	-	5,602	-	2,394	-
7010	Other income	89	-	233	-	346	-	673	-
7020	Other gains and losses	6,603	2	5,692	1	6,898	1	6,135	1
7050	Finance costs	( 197 )	-	( 165 )	-	( 598 )	-	( 311 )	-
		7,738	2	6,302	1	12,248	-	9,431	1
	Profit before tax	91,986	24	80,081	21	188,090	19	151,319	19
7950	Less : Income tax expense (note 6(14))	( 11,058 )	( 3 )	( 8,730 )	( 2 )	( 39,813 )	( 4 )	( 29,213 )	( 4 )
	Profit for the year	80,928	21	71,351	19	148,277	15	122,106	15
8300	Other comprehensive income								
8310	Components of other comprehensive income that will not be reclassified to profit or loss								
8316	Unrealized gains (losses) from investments in equity instruments at fair value through other comprehensive income	42,062	10	47,392	12	15,976	2	240,733	29
8349	Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	-	-	-	-	-	-	-	-
	Components of other comprehensive income that will not be reclassified to profit or loss	42,062	10	47,392	12	15,976	2	240,733	29
8360	Components of other comprehensive income that may be reclassified subsequently to profit or loss								
8361	Exchange differences on translation of foreign financial statements	-	-	36	-	-	-	93	-
8399	Income tax related to components of other comprehensive income that may be reclassified to profit or loss	-	-	-	-	-	-	-	-
8300	Other comprehensive income (after tax)	42,062	10	47,428	12	15,976	2	240,826	29
8500	Total comprehensive income	\$ 122,990	31	118,779	31	164,253	17	362,932	44
	Profit attributable to:								
8610	Equity holders of the parent company	\$ 58,798	16	48,539	13	115,411	11	103,484	13
8620	Non-controlling interest	22,130	5	22,812	6	32,866	4	18,622	2
		\$ 80,928	21	71,351	19	148,277	15	122,106	15
	Total comprehensive income attributable to:								
8710	Equity holders of the parent company	\$ 100,860	25	95,950	25	131,387	14	344,265	42
8720	Non-controlling interest	22,130	6	22,829	6	32,866	3	18,667	2
		\$ 122,990	31	118,779	31	164,253	17	362,932	44
	Earnings per share (note 6(16))								
9750	Basic earnings per share	\$ 1.53		1.26		3.01		2.70	
9850	Diluted earnings per share	\$ 1.53		1.26		3.00		2.69	

See accompanying notes to financial statements.

(English Translation of the Consolidated Financial Statements Originally Issued in Chinese)  
**TSH Biopharm Corporation Ltd. and Subsidiaries**  
**Consolidated Statements of Changes in Equity**  
**For the nine months periods ended September 30, 2025 and 2024**  
(Expressed in Thousands of New Taiwan Dollars)

	Retained Earnings					Other Equity Interest				
	Ordinary share capital	Capital surplus	Legal reserve	Special reserve	Unappropriated retained earnings	Cumulative translation differences of foreign operations	Unrealized gain(loss) on financial assets at fair value through other comprehensive income	Equity attributable to owners of the parent company	Non-controlling interest	Total equity
<b>Balance at January 1, 2024</b>	<u>\$ 383,981</u>	<u>459,500</u>	<u>121,910</u>	<u>4,417</u>	<u>82,232</u>	<u>( 233 )</u>	<u>55,793</u>	<u>1,107,600</u>	<u>158,633</u>	<u>1,266,233</u>
Net income for the period	-	-	-	-	103,484	-	-	103,484	18,622	122,106
Other comprehensive income for the period	-	-	-	-	-	48	240,733	240,781	45	240,826
Total comprehensive income for the period	-	-	-	-	103,484	48	240,733	344,265	18,667	362,932
Appropriation and distribution of retained earnings:										
Legal reserve appropriated	-	-	4,163	-	( 4,163 )	-	-	-	-	-
Cash dividends of ordinary share	-	-	-	-	( 49,150 )	-	-	( 49,150 )	-	( 49,150 )
Reversal of special reserve	-	-	-	( 4,417 )	4,417	-	-	-	-	-
Other changes in capital surplus	-	54	-	-	-	-	-	54	-	54
Increase ( decrease) in non-controlling interest	-	-	-	-	-	-	-	-	51,453	51,453
Disposal of investments in equity instruments designated at fair value through other comprehensive income	-	-	-	-	208,176	-	( 208,176 )	-	-	-
<b>Balance at September 30, 2024</b>	<u><b>\$ 383,981</b></u>	<u><b>459,554</b></u>	<u><b>126,073</b></u>	<u><b>-</b></u>	<u><b>344,996</b></u>	<u><b>( 185 )</b></u>	<u><b>88,350</b></u>	<u><b>1,402,769</b></u>	<u><b>228,753</b></u>	<u><b>1,631,522</b></u>
<b>Balance at January 1, 2025</b>	<u>\$ 383,981</u>	<u>459,554</u>	<u>126,073</u>	<u>-</u>	<u>354,605</u>	<u>( 195 )</u>	<u>67,774</u>	<u>1,391,792</u>	<u>231,176</u>	<u>1,622,968</u>
Net income for the period	-	-	-	-	115,411	-	-	115,411	32,866	148,277
Other comprehensive income for the period	-	-	-	-	-	-	15,976	15,976	-	15,976
Total comprehensive income for the period	-	-	-	-	115,411	-	15,976	131,387	32,866	164,253
Appropriation and distribution of retained earnings:										
Legal reserve appropriated	-	-	32,127	-	( 32,127 )	-	-	-	-	-
Cash dividends of ordinary share	-	-	-	-	( 81,404 )	-	-	( 81,404 )	-	( 81,404 )
Other changes in capital surplus	-	59	-	-	-	-	-	59	-	59
Disposal of subsidiaries	-	-	-	-	-	195	-	195	183	378
Decrease in non-controlling interest	-	-	-	-	-	-	-	-	( 4,860 )	( 4,860 )
<b>Balance at September 30, 2025</b>	<u><b>\$ 383,981</b></u>	<u><b>459,613</b></u>	<u><b>158,200</b></u>	<u><b>-</b></u>	<u><b>356,485</b></u>	<u><b>-</b></u>	<u><b>83,750</b></u>	<u><b>1,442,029</b></u>	<u><b>259,365</b></u>	<u><b>1,701,394</b></u>

See accompanying notes to financial statements.

(English Translation of the Consolidated Financial Statements Originally Issued in Chinese)  
**TSH Biopharm Corporation Ltd. and Subsidiaries**  
**Consolidated Statements of Cash Flows**  
**For the nine months periods ended September 30, 2025 and 2024**  
(Expressed in Thousands of New Taiwan Dollars)

	Nine months periods ended September 30	
	2025	2024
<b>Cash flows from operating activities:</b>		
<b>Profit before tax</b>	\$ 188,090	151,319
<b>Adjustments:</b>		
Adjustments to reconcile profit		
Depreciation	12,473	13,755
Amortization	7,476	7,990
Expected credit losses (gain on reversal)	1,225	1,693
Interest expense	598	311
Interest income	( 5,602 )	( 2,934 )
Dividends income	( 6,557 )	( 6,528 )
Losses on disposal and write-off of property, plant and equipment	-	192
Gain on disposal of subsidiaries	( 1,113 )	-
Profit from lease modification	-	( 1 )
Total adjustment to reconcile profit	8,500	14,478
Changes in operating assets and liabilities:		
Decrease (increase) in notes receivable	( 150 )	7,715
Increase in accounts receivable ( including related parties)	( 148,375 )	( 72,131 )
Decrease in other receivables	270	13
Increase in inventories	( 16,380 )	( 41,443 )
Decrease (increase) in prepayments	9,611	( 1,496 )
Decrease (increase) in other current assets	( 1,739 )	2,716
Increase (decrease) in contract liabilities	834	1,594
Increase (decrease) in notes payable (including related parties)	( 4,642 )	11,315
Increase in accounts payable(including related parties)	110,123	35,940
Decrease in other payables	424	13,178
Increase (decrease) in other current liabilities	( 305 )	( 1,313 )
Total changes in operating assets and liabilities	( 50,329 )	( 43,912 )
Total adjustments	( 41,829 )	( 29,434 )
Cash flows from operations	146,261	121,885
Interest received	4,523	4,395
Interest paid	( 598 )	( 311 )
Income tax paid	( 51,002 )	( 19,094 )
<b>Net cash flows from operating activities</b>	99,184	106,875

(Continued)

(English Translation of the Consolidated Financial Statements Originally Issued in Chinese)  
**TSH Biopharm Corporation Ltd. and Subsidiaries**  
**Consolidated Statements of Cash Flows**  
**For the nine months periods ended September 30, 2025 and 2024**  
(Expressed in Thousands of New Taiwan Dollars)

	Nine months periods ended September 30	
	2025	2024
<b>Cash flows from (used in) investing activities:</b>		
Proceeds from disposal of financial assets at fair value through other comprehensive income	-	183,100
Net cash flow from acquisition of subsidiaries	-	( 242,870 )
Disposal of subsidiaries	1,471	-
Acquisition of property, plant and equipment	( 1,357 )	( 847 )
Disposal of property, plant and equipment	-	250
Increase in guarantee deposits paid	724	109
Acquisition of intangible assets	( 5,796 )	( 643 )
Decrease (increase) in other financial assets - current	( 5,000 )	14,309
Decrease (increase) in other financial assets - non-current	( 2,925 )	-
Increase in prepayment for equipment	( 1,981 )	( 35 )
Dividends received	6,557	6,528
<b>Net cash flows from (used in) investing activities</b>	<u>( 8,307 )</u>	<u>( 40,099 )</u>
<b>Cash flows used in financing activities:</b>		
Payments of lease liabilities	( 9,171 )	( 9,171 )
Cash Dividends paid	( 81,404 )	( 49,150 )
<b>Net cash flows used in financing activities</b>	<u>( 90,575 )</u>	<u>( 58,324 )</u>
Effect of fluctuations in exchange rate	-	69
Net increase in cash and cash equivalents	302	8,521
Cash and cash equivalents at beginning of period	588,342	576,585
Cash and cash equivalents at end of period	<u>\$ 588,644</u>	<u>585,106</u>

See accompanying notes to financial statements.

(English Translation of the Consolidated Financial Statements Originally Issued in Chinese)  
**TSH BIOPHARM CORPORATION LTD. and Subsidiaries**  
**Notes to the Consolidated Financial Statements**  
**September 30, 2025 and 2024**

(Amounts expressed in thousands of New Taiwan Dollars unless otherwise specified)

**1. History and organization**

TSH Biopharm Corporation Ltd. (the “Company”) was incorporated on September 21, 2010. The Company's registered office address is 3F.-1, No. 3-1, Park St., Nangang Dist., Taipei City 115, Taiwan (R.O.C.). The shares of the Company have been listed on the Taipei Exchange (“TPEX”) since April 2012. The main activity of the Company and its subsidiaries (the “Group”) is in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services.

**2. Approval date and procedures of the financial statements**

The accompanying consolidated financial statements were authorized for issue by the Board of Directors on November 5, 2025.

**3. Application of new standards, amendments and interpretations**

- (1) The impact of the International Financial Reporting Standards (“IFRSs”) endorsed by the Financial Supervisory Commission, R.O.C. (“FSC”) which have already been adopted.

The Group believes that the adoption of the following IFRSs from January 1, 2025 would not have any material impact on its consolidated financial statements.

- Amendments to IAS 21 “Lack of Exchangeability”

- (2) The impact of the International Financial Reporting Standards (“IFRSs”) endorsed by the Financial Supervisory Commission, R.O.C. (“FSC”) which have not been adopted.

The assessment of the Group’s application of the newly amended IFRSs, effective from January 1, 2026, indicates that it will not have a significant impact on the consolidated financial statements.

- IFRS 17 “Insurance Contracts” and amendments to IFRS 17 “Insurance Contracts”
- Amendments to IFRS 9 and IFRS 7 “Amendments to the Classification and Measurement of Financial Instruments”
- Annual Improvements to IFRS Accounting Standards
- Amendments to IFRS 9 and IFRS 7 “Contracts for Renewable Electricity”

- (3) The impact of IFRS issued by IASB but not yet endorsed by the FSC

The IASB has issued standards and interpretations that have not yet been endorsed by the FSC. The potential impact on the Group is as follows:

Newly issued or revised standards	Major revisions	Effective Date of the Council's Publication
IFRS 18 “Presentation and Disclosure in Financial Statements”	The new standard introduces three types of income and expenses, two subtotal items in the income statement, and a single note regarding management performance measurement. These three amendments strengthen guidance on how information is disaggregated in financial statements, providing users with better and more consistent information, and will impact all companies.	January 1, 2027

Newly issued or revised standards	Major revisions	Effective Date of the Council's Publication
IFRS 18 “Presentation and Disclosure in Financial Statements”	<ul style="list-style-type: none"> <li>• <b>More Structured Income Statement:</b> Under current standards, companies use different formats to express their operating results, making it difficult for investors to compare the financial performance of different companies. The new standard adopts a more structured income statement, introducing a subtotal of "operating profit" based on new definitions and stipulating that all income and expenses be classified into three new distinct categories based on the company's primary operating activities.</li> <li>• <b>Management Performance Measurement (MPMs):</b> The new standard introduces the definition of Management Performance Measurement and requires companies to explain in a single note to the financial statements for each performance measure why it provides useful information, how it is calculated, and how the measure is adjusted to reconcile with the amounts recognized under International Financial Reporting Standards accounting standards.</li> <li>• <b>More Detailed Information:</b> The new standard includes guidance on how companies should enhance the grouping of information in financial statements. This includes guidance on whether information should be included in the primary financial statements or further disaggregated in the notes.</li> </ul>	<p>January 1, 2027</p> <p>Note: On September 25, 2025, the FSC announced in a press release that publicly traded companies will be required to adopt IFRS 18 starting from fiscal year 2028. Furthermore, enterprises that wish to early adopt IFRS 18 may do so—subject to FSC approval—once IFRS 18 has been formally endorsed by the FSC.</p>

The Group is currently assessing the impact of the aforementioned standards and interpretations on the financial position and operating results of the consolidated company. Relevant impacts will be disclosed upon completion of the assessment.

The Group anticipates that the following additional yet to be endorsed new releases and amendments will not have a significant impact on the consolidated financial statements.

- Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets Between an Investor and Its Associate or Joint Venture”
- IFRS 19 “Subsidiaries without Public Accountability: Disclosures”

#### 4. Summary of significant accounting policies

##### (1) Statement of compliance

The accompanying consolidated financial statements have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers (hereinafter referred to as “the Regulations”) and IAS 34, Interim Financial Reporting, as endorsed and issued into effect by the FSC. These consolidated financial statements do not present all the disclosures required for a complete set of annual consolidated financial statements prepared under the Regulations Governing the Preparation of Financial Reports by Securities Issuers (hereinafter referred to as “the Regulations”) and the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations endorsed and issued into effect by the Financial Supervisory Commission, R.O.C. (hereinafter referred to as “IFRSs endorsed by FSC”).

Excepted for the accounting policies mentioned below, the significant accounting policies adopted in the interim financial statements is the same as those in the financial statements for the year ended December 31, 2024. For the related information, please refer to Note 4 of the financial statements for the year ended December 31, 2024.

##### (2) Basis of consolidation

###### A. Subsidiaries included in the consolidated financial statements:

<u>Name of Investor</u>	<u>Name of subsidiary</u>	<u>Main Business Activities</u>	<u>Percentage of Ownership</u>			<u>Note</u>
			<u>September 30, 2025</u>	<u>December 31, 2024</u>	<u>September 30, 2024</u>	
TSH Biopharm Corporation Ltd.	Chuang Yi Biotech Co. Ltd.	Selling of health food	51.60%	51.60%	51.60%	
TSH Biopharm Corporation Ltd.	Top Pharma Medical-wares Co., Ltd.	Selling of medicine and dietary supplement	51.00%	51.00%	51.00%	Note 1 、 2
TSH Biopharm Corporation Ltd.	TOP Biological Technology Company Limited.	Food manufacturing industry	-%	51.00%	51.00%	Note 1 、 2
Chuang Yi Biotech Co. Ltd.	Immortal Fame Global Ltd.	General export trade and investment in various production enterprises	-%	100.00%	100.00%	Note 3
Immortal Fame Global Ltd.	Chuang Yi (Shanghai) Trading Co., Ltd	Selling of dietary supplement	-%	100.00%	100.00%	Note 3

Note 1 : On March 11, 2024, the Company acquired 51% of the issued and outstanding common shares of Top Pharma Medical-wares Co., Ltd. and TOP Biological Technology Company Limited. by resolution of the board of directors, and completed the share delivery on April 9, 2024.

Note 2: To strengthen the integration of group resources, the Company's Board of Directors approved the merger of Top Pharma Medical-wares Co., Ltd. and TOP Biological Technology Company Limited. on November 8, 2024. Top Pharma Medical-wares Co., Ltd. will be the surviving company, while TOP Biological Technology Company Limited. will be the dissolved company. The merger base date is set as January 1, 2025, and the change was approved by the competent authority on March 3, 2025.

Note 3 : The merged company was resolved by the board of directors to be disposed of, and the transaction was completed on January 6, 2025.

B. Subsidiaries not included in the consolidated financial statements: None.

(3) Income taxes

The Group measures and discloses interim period income tax expense in accordance with paragraph B12 of IAS 34, Interim Financial Reporting.

Income tax expense for the period is best estimated by multiplying pre-tax income of the interim period by a projected annual effective tax rate, and is recognized as current tax expense.

Income taxes that are recognized directly in equity or other comprehensive income are measured in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the corresponding tax bases at the tax rates that are expected to be applied in the year in which the asset is realized or the liability is settled.

**5. Significant accounting assumptions and judgments, and major sources of estimation uncertainty**

The preparation of the consolidated financial statements in conformity with the Regulations and IAS 34, Interim Financial Reporting, as endorsed and issued into effect by the FSC requires management to make judgments, estimates and assumptions that affect the application of the accounting policies and the reported amount of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Except for the following disclosure, in preparing the consolidated financial statements, critical accounting judgments and key sources of estimations and assumptions uncertainty used by management in the application of accounting policies are consistent with those described in Note 5 of the financial statements for the year ended December 31, 2024.

**6. Explanation of significant accounts**

Except for the following disclosure, the significant account disclosure in the consolidated financial statements don't have significant difference with those in the consolidated financial statements for the year ended December 31, 2024. For the related information, please refer to Note 6 of the consolidated financial statements for the year ended December 31, 2024.

(1) Cash and cash equivalents

	September 30, 2025	December 31, 2024	September 30, 2024
Petty cash	\$ 170	170	173
Cash in banks	588,474	588,172	584,933
	<u>\$ 588,644</u>	<u>588,342</u>	<u>585,106</u>

A. The above cash and cash equivalents were not pledged as collateral.

B. Time deposits which do not meet the definition of cash equivalents are accounted for under other financial assets-current. As of September 30, 2025, December 31, 2024 and September 30 2024, the amount of time deposits were \$237,000 thousand, \$232,000 thousand and \$127,000 thousand respectively.

C. Please refer to note 6(20) for the foreign currency risk and sensitivity analysis of the financial assets of the Group.

(2) Financial assets at fair value through other comprehensive income

	September 30, 2025	December 31, 2024	September 30, 2024
Equity instruments at fair value through other comprehensive income :			
Current	\$ 88,876	77,015	98,307
Non - current	190,329	186,213	183,009
	<b>\$ 279,205</b>	<b>263,228</b>	<b>281,316</b>

A. Equity instruments at fair value through other comprehensive income

The Group holds such equity investments as long-term strategic investment that is not held for trading purposes; thus, they are designated as equity investment measured at fair value through other comprehensive income.

There were no disposals of strategic investments and transfers of any cumulative gain or loss within equity relating to these investments for the nine-month periods ended September 30, 2025.

During the period from January 1 to September 30, 2024, the Group disposed of a portion of financial assets designated at fair value through other comprehensive income. The fair value at the time of disposal was \$221,121 thousand, and the disposal gain amounted to \$208,176 thousand. Accordingly, the gain on disposal was reclassified from other equity to retained earnings.

B. Please refer to note 6(20) for credit and market risk information.

C. The above financial assets were not pledged as collateral.

(3) Notes receivable and accounts receivable (including related parties)

	September 30, 2025	December 31, 2024	September 30, 2024
Notes receivable	\$ 11,218	11,048	11,405
Accounts receivable-measured at amortized cost	351,523	203,168	323,889
Less: Allowance for expected credit losses	(3,758)	(2,533)	(3,463)
	<b>\$ 358,983</b>	<b>211,683</b>	<b>331,831</b>

The Group applies the simplified approach to provide for its expected credit losses, which permit the use of lifetime expected loss provision for all receivables. To measure the expected credit losses, notes and accounts receivable have been grouped based on shared credit risk characteristics and the days past due, as well as forward looking information. The loss allowance provision was determined as follows:

	September 30, 2025		
	Gross carrying amount	Weighted-average loss rate	Loss allowance provision
Not past due	\$ 362,153	0.98%~1%	3,752
Past due 1~60 days	535	1%	5
Past due 61~120 days	53	1%	1
	<b>\$ 362,741</b>		<b>3,758</b>

	December 31, 2024		
	Gross carrying amount	Weighted-average loss rate	Loss allowance provision
Not past due	\$ 214,006	1%~1.29%	2,531
Past due 1~60 days	210	1%	2
	<b>\$ 214,216</b>		<b>2,533</b>
	September 30, 2024		
	Gross carrying amount	Weighted-average loss rate	Loss allowance provision
Not past due	\$ 333,347	0%~1%	3,289
Past due 1~60 days	1,947	1%~11.52%	174
Past due 61~120 days	-	-	-
	<b>\$ 335,294</b>		<b>3,463</b>

The movement in the allowance for notes and accounts receivable was as follows:

For the nine months periods ended September 30		
	2025	2024
Balance on January 1, 2025	\$ 2,533	1,770
Impairment losses recognized	1,225	1,693
Balance on September 30, 2025	<b>\$ 3,758</b>	<b>3,463</b>

The aforementioned notes and account receivables of the Group had not been pledged as collateral as of September 30 2025, December 31 2024 and September 30 ,2024.

#### (4) Inventories

	September 30, 2025	December 31, 2024	September 30, 2024
Merchandise	\$ 108,814	111,535	114,214
Work in progress and finished goods	49,846	42,946	33,841
Raw materials and supplies	51,566	40,544	53,105
Less: Allowance for inventory market decline and obsolescence	(17,771)	(18,950)	(28,553)
	<b>\$ 192,455</b>	<b>176,075</b>	<b>172,607</b>

The details of cost of goods sold were as follows:

	For the three months periods ended September 30,		For the nine months periods ended September 30,	
	2025	2024	2025	2024
Reclassification of inventory sold	\$ 220,588	200,779	478,831	376,478
Loss for market price decline (gain on reversal) and obsolescence of inventory	(149)	(567)	(1,179)	10,956
	<b>\$ 220,439</b>	<b>200,212</b>	<b>477,652</b>	<b>387,434</b>

During the nine-month periods ended September 30, 2025 and 2024 and the year ended December 31, 2024, the Group had not pledged any inventories as collateral.

(5) Acquisition of subsidiary

On April 9, 2024 (the acquisition date), the Company acquired 51% of the outstanding shares of Top Pharma Medical-wares Co., Ltd. and TOP Biological Technology Company Limited. for \$301,451 thousand, thereby gaining control over these companies. Consequently, the Group's equity in Top Pharma Medical-wares Co., Ltd. and TOP Biological Technology Company Limited. increased to 51%. Top Pharma Medical-wares Co., Ltd. and TOP Biological Technology Company Limited. are engaged in the manufacturing and promotion of health food products.

The acquisition of control over Top Pharma Medical-wares Co., Ltd. and TOP Biological Technology Company Limited. has allowed the combined company to expand its operational scale, enhance its operational performance, and increase its competitiveness.

A. Transfer Pricing

	Top Pharma Medical-wares	TOP Biological Technology
Cash	<u>\$ 257,121</u>	<u>44,330</u>

B. Identifiable assets acquired and liabilities assumed

Fair value details of identifiable assets acquired and liabilities assumed as of the acquisition date are as follows :

	Top Pharma Medical-wares	TOP Biological Technology
Cash and cash equivalents	\$ 55,135	3,446
Notes receivable and accounts receivable	49,520	11,255
Inventories	5,185	7,584
Other financial assets	25,000	-
Property, plant and equipment	215	4,967
Right-of-use assets	4,955	1,949
Intangible assets	318	-
Other non-current assets	2,894	3,640
Notes payable and accounts payable	(37,105)	(11,391)
Lease liabilities	(5,049)	(2,023)
Current tax liabilities	(5,356)	(1,182)
Other liabilities	(8,397)	(554)
	<u>\$ 87,315</u>	<u>17,691</u>

C. Goodwill

The goodwill recognized from the acquisition is as follows:

	Top Pharma Medical-wares	TOP Biological Technology
Transfer pricing	\$ 257,121	44,330
Add : Non-controlling interest ( measure net identifiable assets in proportion to non-controlling interests)	42,784	8,669
Less : Fair value of net identifiable assets	(87,315)	(17,691)
Goodwill	<u>\$ 212,590</u>	<u>35,308</u>

(6) Material non-controlling interests of subsidiaries

The material non-controlling interests of subsidiaries were as follows:

<u>Subsidiaries</u>	<u>Main operation place</u>	<u>Percentage of non- controlling interests</u>		
		<u>September 30,</u> <u>2025</u>	<u>December 31,</u> <u>2024</u>	<u>September 30,</u> <u>2024</u>
Chuang Yi Biotech Co. Ltd.	Taiwan	48.40%	48.40%	48.40%
Top Pharma Medical-wares Co., Ltd.	"	49.00%	49.00%	49.00%
TOP Biological Technology Company Limited.	"	-%	49.00%	49.00%

The following information of the aforementioned subsidiaries have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers. Included in these information are the fair value adjustment made during the acquisition and relevant difference in accounting principles between the Group as at the acquisition date. Intragroup transactions were not eliminated in this information.

A. Chuang Yi Biotech Co. Ltd.'s collective financial information

	<u>September 30,</u> <u>2025</u>	<u>December 31,</u> <u>2024</u>	<u>September 30,</u> <u>2024</u>
Current assets	\$ 503,388	339,124	441,006
Non-current assets	34,907	39,703	39,850
Current liabilities	(169,386)	(47,973)	(141,598)
Non- current liabilities	(439)	(1,743)	(25)
Net assets	<u>\$ 368,470</u>	<u>329,111</u>	<u>339,233</u>
Net assets attributed to non-controlling interests	<u>\$ 178,339</u>	<u>159,290</u>	<u>164,189</u>

	<u>For the three months periods</u> <u>ended September 30,</u>		<u>For the nine months periods</u> <u>ended September 30,</u>	
	<u>2025</u>	<u>2024</u>	<u>2025</u>	<u>2024</u>
Sales revenue	<u>\$ 189,021</u>	<u>169,588</u>	<u>297,361</u>	<u>222,565</u>
Net income	\$ 34,523	34,432	38,981	11,385
Other comprehensive income	-	36	378	93
Comprehensive income	<u>\$ 34,523</u>	<u>34,468</u>	<u>39,359</u>	<u>11,478</u>
Loss, attributable to non-controlling interests	<u>\$ 16,709</u>	<u>16,665</u>	<u>18,867</u>	<u>5,510</u>
Comprehensive income, attributable to non-controlling interests	<u>\$ 16,709</u>	<u>16,682</u>	<u>19,050</u>	<u>5,555</u>

	For the nine months periods ended September 30, 2025	For the nine months periods ended September 30, 2024
Net cash flows from operating activities	\$ 21,711	7,041
Net cash flows from investing activities	3,542	11
Net cash flows from financing activities	(1,281)	-
Effect of exchange rate changes on cash and cash equivalents	-	92
Net decrease in cash and cash equivalents	<u>\$ 23,972</u>	<u>7,144</u>

B. Top Pharma Medical-wares Co., Ltd.'s collective financial information

	September 30, 2025	December 31, 2024	September 30, 2024
Current assets	\$ 218,825	192,868	167,376
Non-current assets	268,158	224,356	223,699
Current liabilities	(66,906)	(75,456)	(62,911)
Non- current liabilities	(6,821)	(5,348)	(5,305)
Net assets	<u>\$ 413,256</u>	<u>336,420</u>	<u>322,859</u>
Net assets attributed to non-controlling interests	<u>\$ 81,026</u>	<u>60,677</u>	<u>54,032</u>

	For the three months periods ended September 30, 2025	For the three months periods ended September 30, 2025	For the nine months periods ended September 30, 2025	From April 9, 2024 to September 30, 2024
Sales revenue	<u>\$ 83,954</u>	<u>92,137</u>	<u>243,996</u>	<u>175,700</u>
Net income	\$ 11,064	11,038	28,570	22,954
Other comprehensive income	-	-	-	-
Comprehensive income	<u>\$ 11,064</u>	<u>11,038</u>	<u>28,570</u>	<u>22,954</u>
Net income attributable to non-controlling interests	<u>\$ 5,421</u>	<u>5,409</u>	<u>13,999</u>	<u>11,247</u>

	For the nine months periods ended September 30, 2025	For the nine months periods ended September 30, 2024
Net cash flows from operating activities	\$ 11,131	19,877
Net cash flows from investing activities	1,647	898
Net cash flows from financing activities	(5,508)	(4,710)
Net increase in cash and cash equivalents	<u>\$ 7,270</u>	<u>16,065</u>

C. TOP Biological Technology Company Limited. 's collective financial information

	December 31, 2024	September 30, 2024
Current assets	\$ 29,892	26,095
Non-current assets	41,237	41,952
Current liabilities	(12,945)	(11,245)
Non- current liabilities	-	-
Net assets	<u>\$ 58,184</u>	<u>56,802</u>
Net assets attributed to non-controlling interests	<u>\$ 11,209</u>	<u>10,532</u>

	For the three months periods ended September 30, 2024	From April 9, 2024 to September 30, 2024
Sales revenue	<u>\$ 16,366</u>	<u>\$ 32,329</u>
Net income	\$ 1,504	\$ 3,804
Other comprehensive income	-	-
Comprehensive income	<u>\$ 1,504</u>	<u>\$ 3,804</u>
Net income attributable to non-controlling interests	<u>\$ 737</u>	<u>\$ 1,864</u>

	For the nine months periods ended September 30, 2024
Net cash flows from operating activities	\$ (2,595)
Net cash flows from investing activities	(352)
Net cash flows from financing activities	(1,078)
Net increase in cash and cash equivalents	<u>\$ (4,025)</u>

(7) Property, plant and equipment

The details of changes in the cost, depreciation, and impairment losses of property, plant, and equipment of the Group are as follows:

	<b>Land</b>	<b>Building and construction</b>	<b>Machinery equipment</b>	<b>Office equipment</b>	<b>Other equipment</b>	<b>Total</b>
Cost:						
Balance on January 1, 2025	\$ 5,846	14,195	22,208	7,980	17,493	67,722
Additions	-	-	305	179	873	1,357
Disposals	-	-	-	(33)	-	(33)
Disposal of subsidiaries	-	-	(459)	-	-	(459)
Balance on September 30, 2025	<u>\$ 5,846</u>	<u>14,195</u>	<u>22,054</u>	<u>8,126</u>	<u>18,366</u>	<u>68,587</u>
Balance on January 1, 2024	\$ 5,846	14,195	12,845	9,641	10,641	53,168
Acquired through business acquisition	-	-	9,591	1,096	9,774	20,461
Additions	-	-	392	102	353	847
Disposals	-	-	(635)	(3)	-	(638)
Effect of exchange rate changes	-	-	20	-	-	20
Balance on September 30, 2024	<u>\$ 5,846</u>	<u>14,195</u>	<u>22,213</u>	<u>10,836</u>	<u>20,768</u>	<u>73,858</u>
Accumulated depreciation and impairment losses:						
Balance on January 1, 2025	\$ -	10,756	16,357	6,868	13,752	47,733
Depreciation	-	294	1,717	512	634	3,157
Disposals	-	-	-	(33)	-	(33)
Disposal of subsidiaries	-	-	(435)	-	-	(435)
Balance on September 30, 2025	<u>\$ -</u>	<u>11,050</u>	<u>17,639</u>	<u>7,347</u>	<u>14,386</u>	<u>50,422</u>
Balance on January 1, 2024	\$ -	5,619	8,333	6,860	6,997	27,809
Acquired through business acquisition	-	-	5,580	938	8,761	15,279
Depreciation	-	653	2,050	998	1,063	4,764
Disposals	-	-	(193)	(3)	-	(196)
Effect of exchange rate changes	-	-	19	-	-	19
Balance on September 30, 2024	<u>\$ -</u>	<u>6,272</u>	<u>15,789</u>	<u>8,793</u>	<u>16,821</u>	<u>47,675</u>
Book value :						
Balance on January 1, 2025	<u>\$ 5,846</u>	<u>3,439</u>	<u>5,851</u>	<u>1,112</u>	<u>3,741</u>	<u>19,989</u>
Balance on September 30, 2025	<u>\$ 5,846</u>	<u>3,145</u>	<u>4,415</u>	<u>779</u>	<u>3,980</u>	<u>18,165</u>
Balance on January 1, 2024	<u>\$ 5,846</u>	<u>8,576</u>	<u>4,512</u>	<u>2,781</u>	<u>3,644</u>	<u>25,359</u>
Balance on September 30, 2024	<u>\$ 5,846</u>	<u>7,923</u>	<u>6,424</u>	<u>2,043</u>	<u>3,947</u>	<u>26,183</u>

(8) Right-of-use assets

The details of changes in the cost and depreciation of leased buildings and transportation-related costs of the Group are as follows:

	Building and construction	Transportation Equipment	Total
Cost :			
Balance on January 1, 2025	\$ 14,928	15,291	30,219
Additions	3,286	4,365	7,651
Decrease	(1,503)	(3,405)	(4,908)
Balance on September 30, 2025	<u><b>\$ 16,711</b></u>	<u><b>16,251</b></u>	<u><b>32,962</b></u>
Balance on January 1, 2024	\$ 17,630	-	17,630
Acquired through business acquisition	5,053	15,982	21,035
Additions	-	7,537	7,537
Decrease	(195)	(6,778)	(6,973)
Balance on September 30, 2024	<u><b>\$ 22,488</b></u>	<u><b>16,741</b></u>	<u><b>39,229</b></u>
Accumulated depreciation :			
Balance on January 1, 2025	\$ 4,068	5,726	9,794
Depreciation	5,289	4,027	9,316
Decrease	(1,503)	(3,405)	(4,908)
Balance on September 30, 2025	<u><b>\$ 7,854</b></u>	<u><b>6,348</b></u>	<u><b>14,202</b></u>
Balance on January 1, 2024	\$ 10,314	-	10,314
Acquired through business acquisition	2,838	11,293	14,131
Additions	6,246	2,745	8,991
Decrease	(123)	(6,778)	(6,901)
Balance on September 30, 2024	<u><b>\$ 19,275</b></u>	<u><b>7,260</b></u>	<u><b>26,535</b></u>
Book value :			
Balance on January 1, 2025	<u><b>\$ 10,860</b></u>	<u><b>9,565</b></u>	<u><b>20,425</b></u>
Balance on September 30, 2025	<u><b>\$ 8,857</b></u>	<u><b>9,903</b></u>	<u><b>18,760</b></u>
Balance on January 1, 2024	<u><b>\$ 7,316</b></u>	<u><b>-</b></u>	<u><b>7,316</b></u>
Balance on September 30, 2024	<u><b>\$ 3,213</b></u>	<u><b>9,481</b></u>	<u><b>12,694</b></u>

(9) Intangible assets

The details of changes in the cost, amortization, and impairment losses of intangible assets of the Group are as follows:

	<b>Computer software</b>	<b>Patent and drug permit license</b>	<b>Drug distributio n license</b>	<b>Goodwill</b>	<b>Others</b>	<b>Total</b>
Cost :						
Balance on January 1, 2025	\$ 6,880	14,600	70,000	247,898	77	339,455
Additions	2,499	3,297	-	-	-	5,796
Reclassification	-	6,122	-	-	-	6,122
Disposals	(476)	-	-	-	-	(476)
Balance on September 30, 2025	<u>\$ 8,903</u>	<u>24,019</u>	<u>70,000</u>	<u>247,898</u>	<u>77</u>	<u>350,897</u>
Balance on January 1, 2024	\$ 4,609	14,600	70,000	-	-	89,209
Acquired through business acquisitionr (Note 6(5))	1,253	-	-	247,898	87	249,238
Additions	643	-	-	-	-	643
Balance on September 30, 2024	<u>\$ 6,505</u>	<u>14,600</u>	<u>70,000</u>	<u>247,898</u>	<u>87</u>	<u>339,090</u>
Accumulated depreciation and impairment losses:						
Balance on January 1, 2025	\$ 4,916	11,696	35,124	-	67	51,803
Amortisation	989	1,726	4,755	-	6	7,476
Disposals	(476)	-	-	-	-	(476)
Balance on September 30, 2025	<u>\$ 5,429</u>	<u>13,422</u>	<u>39,879</u>	<u>-</u>	<u>73</u>	<u>58,803</u>
Balance on January 1, 2024	\$ 2,568	4,223	28,782	-	-	35,573
Acquired through business acquisition (Note 6(5))	951	-	-	-	71	1,022
Amortisation	1,025	2,205	4,756	-	4	7,990
Balance on September 30, 2024	<u>\$ 4,544</u>	<u>6,428</u>	<u>33,538</u>	<u>-</u>	<u>75</u>	<u>44,585</u>
Book value :						
Balance on January 1, 2025	<u>\$ 1,964</u>	<u>2,904</u>	<u>34,876</u>	<u>247,898</u>	<u>10</u>	<u>287,652</u>
Balance on September 30, 2025	<u>\$ 3,474</u>	<u>10,597</u>	<u>30,121</u>	<u>247,898</u>	<u>4</u>	<u>292,094</u>
Balance on January 1, 2024	<u>\$ 2,041</u>	<u>10,377</u>	<u>41,218</u>	<u>-</u>	<u>-</u>	<u>53,636</u>
Balance on September 30, 2024	<u>\$ 1,961</u>	<u>8,172</u>	<u>36,462</u>	<u>247,898</u>	<u>12</u>	<u>294,505</u>

(10) Other current assets and other non-current assets

The details of other current assets and other non-current assets were as follows:

	<b>September 30, 2025</b>	<b>December 31, 2024</b>	<b>September 30, 2024</b>
Other current financial assets	\$ 237,000	232,000	127,000
Other current assets	2,151	412	1,274
Long-term prepayments	4,994	6,417	6,417
Refundable deposits	8,026	8,750	9,107
	<b><u>\$ 252,171</u></b>	<b><u>247,579</u></b>	<b><u>143,798</u></b>

A. Other current financial assets were time deposits which did not meet the definition of cash equivalents. For further credit and market risk information, please refer to note 6(20).

B. The long-term prepayments primarily serve to acquire intangible assets, representing payments made before the intangible assets are ready for use. Please refer to Note 9 for detailed explanations regarding related unrecognized contractual commitments.

(11) Other payables

The details of other payables were as follows:

	<b>September 30, 2025</b>	<b>December 31, 2024</b>	<b>September 30, 2024</b>
Salaries and compensation of employees and directors	\$ 46,085	52,920	43,242
Research expenses	3,866	2,418	4,752
Commission	1,594	1,353	1,260
Dividends	4,860	-	-
Others	39,549	34,017	39,099
	<b><u>\$ 95,954</u></b>	<b><u>90,708</u></b>	<b><u>88,353</u></b>

(12) Lease liabilities

The carrying amounts of lease liabilities were as follows:

	<b>September 30, 2025</b>	<b>December 31, 2024</b>	<b>September 30, 2024</b>
Current	<b><u>\$ 10,836</u></b>	<b><u>10,101</u></b>	<b><u>7,453</u></b>
Non-current	<b><u>\$ 8,075</u></b>	<b><u>10,330</u></b>	<b><u>5,305</u></b>

For the maturity analysis, please refer to note 6(20) financial instruments.

The amounts recognized in profit or loss were as follows:

	For the three months periods ended September 30		For the nine months periods ended September 30	
	2025	2024	2025	2024
Interest on lease liabilities	<u>\$ 197</u>	<u>150</u>	<u>598</u>	<u>296</u>
Expenses of short-term leases	<u>\$ 464</u>	<u>289</u>	<u>1,251</u>	<u>689</u>
Expenses relating to leases of low-value assets, excluding short-term leases of low-value assets	<u>\$ 49</u>	<u>102</u>	<u>110</u>	<u>146</u>

The amounts recognized in the statement of cash flows for the Group were as follows:

	For the nine months periods ended September 30	
	2025	2024
Total cash outflow for leases	<u>\$ 11,130</u>	<u>10,305</u>

A. Real estate and transportation equipment leases

The Group leased buildings for its office and plant with lease term of 2 to 13.5 years. Some leases include an option to renew the lease for an additional period of the same duration after the end of the contract term.

The lease payment of the plant contract is calculated on basis of the purchase quantity of the plant leased by the Group during the lease period. It is a variable lease payment that is not included in the measurement of the lease liability. Therefore, the Group will pay the relevant lease payment during the lease period to recognize the expense.

B. Other leases

The Group lease office equipment with lease term of 0.5 to 5 years, these leases are leases of short-term or low-value items. The Group has elected not to recognize right-of-use assets and lease liabilities for these leases.

(13) Employee benefits

Defined contribution plans

The Group allocates 6% of each employee's monthly wages to the labor pension personal account at the Bureau of Labor Insurance in accordance with the provisions of the Labor Pension Act. Under these defined contribution plans, the Group allocates a fixed amount to the Bureau of Labor Insurance without additional legal or constructive obligation.

The pension expenses of the Group under the defined contribution plan are as follows and have been contributed to the Bureau of Labor Insurance.

	For the three months periods ended September 30		For the nine months periods ended September 30	
	2025	2024	2025	2024
Cost of goods sold	\$ 91	59	280	59
Selling expenses	1,772	1,952	5,417	4,306
Administrative expenses	458	697	1,462	2,267
Research and development expenses	113	92	330	256
	<u>\$ 2,434</u>	<u>2,800</u>	<u>7,489</u>	<u>6,888</u>

(14) Income taxes

A. Income tax expense

Details of the Group's income tax expenses are as follows:

	For the three months periods ended September 30		For the nine months periods ended September 30	
	2025	2024	2025	2024
Current income tax expense				
Current period	\$ 11,005	8,730	29,334	29,004
Adjustments to current income tax of prior periods	-	-	39	209
Surtax on undistributed earnings	53	-	10,440	-
Income tax expenses	<u>\$ 11,058</u>	<u>8,730</u>	<u>39,813</u>	<u>29,213</u>

B. Status of income tax assessment

The Group's tax returns for the years through 2023 were assessed by the Taipei National Tax Administration.

(15) Capital and other equity

Except as described below, there were no significant changes in equity of the Group for the nine months periods ended September 30 2025 and 2024. Please refer to Note 6(15) in the consolidated financial statements for the year ended December 31, 2024 for relevant information..

A. Capital surplus

The balances of capital surplus were as following:

	September 30, 2025	December 31, 2024	September 30, 2024
Share Capital	\$ 458,977	458,977	458,977
Others	636	577	577
	<u>\$ 459,613</u>	<u>459,554</u>	<u>459,554</u>

B. Retained earnings

The Group's article of incorporation stipulates that Group's net earnings should first be used to offset the prior years' deficits, if any, before paying any income taxes. Of the remaining balance, 10% is to be appropriated as legal reserve, until the accumulated legal reserve equals the Group's

paid-in capital. In addition, a special reserve in accordance with applicable laws and regulations shall also be set aside. Then, any remaining profit, together with any undistributed retained earnings, shall be distributed according to the proposal by the Board of Directors and submitted to the stockholders' meeting for approval.

To enhance the Group's financial structure and maintain investors' equity, the Group adopts a stable dividends policy in which earnings distribution cannot be less than 50% of distributable earnings, and cash dividends payment has to be over than 50% of the distribution.

(A) Legal reserve

When a Group incurs no loss, it may, pursuant to a resolution by a shareholders' meeting, distribute its legal reserve by issuing new shares or by distributing cash, and only the portion of legal reserve which exceeds 25% of capital may be distributed.

(B) Special reserve

The Group has set aside the same amount of special surplus reserve in accordance with the requirements of the Financial Supervisory Commission's Order No. 1010012865 dated April 6, 2012. When distributing the distributable surplus, the Group will record the deduction for other shareholders' equity that occurred in the current year. The difference between the net amount of the item and the special surplus reserve balance mentioned in the previous paragraph shall be included in the special surplus reserve from the profit and loss of the current period and the undistributed surplus of the previous period. The special surplus reserve shall not be distributed. If the amount of deductions from other shareholders' equity is subsequently reversed, the reversed portion of the earnings may be distributed.

(C) Earnings distribution

The company resolved at the shareholders' annual meetings on May 28, 2025, and May 24, 2024, to distribute the profits for the fiscal years 2024 and 2023. The dividend amounts to be distributed to shareholders are as follows:

	For the year ended December 31,			
	2024		2023	
	Amount per share (dollars)	Total amount	Amount per share (dollars)	Total amount
Dividends distributed to ordinary shareholders:				
Cash	\$ 2.12	<u>81,404</u>	1.28	<u>49,150</u>

### C. Other equity interests

	Exchange differences on translation of foreign financial statements	Unrealized gains on financial assets measured at fair value through other comprehensive income	Total
Balance on January 1, 2025	( \$ 195 )	67,774	67,579
Disposal of subsidiaries	195	-	195
Unrealized gains on financial assets measured at fair value through other comprehensive income	-	15,976	15,976
Balance on September 30, 2025	<u>\$ -</u>	<u>83,750</u>	<u>83,750</u>
Balance on January 1, 2024	( \$ 233 )	55,793	55,560
Exchange differences on translation of foreign financial statements	48	-	48
Unrealized gains on financial assets measured at fair value through other comprehensive income	-	240,733	240,733
Disposal of equity instruments measured at fair value through other comprehensive income	( 208,176 )	( 208,176 )	( 208,176 )
Banlance on September 30, 2024	<u>( \$ 185 )</u>	<u>88,350</u>	<u>88,165</u>

### D. Non-controlling interests

	For the nine months periods ended September 30	
	2025	2024
Begininig balance	\$ 231,176	158,633
Attributable to non-controlling interests:		
Net income (loss)	32,866	18,622
Disposal of subsidiaries	183	-
Exchange differences on translation of foreign financial statements	-	45
Dividends distributed by subsidiaries to non- controlling interests	( 4,860 )	-
Increase on non-controlling interest	-	51,453
Ending balance	<u>\$ 259,365</u>	<u>228,753</u>

(16) Earnings per share

The calculation of basic earnings per share and diluted earnings per share were as follows:

	For the three months periods ended September 30		For the nine months periods ended September 30	
	2025	2024	2025	2024
Basic earnings per share				
Net income attributable to ordinary shareholders	<u>\$ 58,798</u>	<u>48,539</u>	<u>115,411</u>	<u>103,484</u>
Weighted-average number of ordinary shares	<u>38,398</u>	<u>38,398</u>	<u>38,398</u>	<u>38,398</u>
	<u>\$ 1.53</u>	<u>1.26</u>	<u>3.01</u>	<u>2.70</u>
Diluted earnings per share				
Net income attributable to ordinary shareholders (after adjustment of dilutive potential ordinary shares)	<u>\$ 58,798</u>	<u>48,539</u>	<u>115,411</u>	<u>103,484</u>
Weighted-average number of ordinary shares	38,398	38,398	38,398	38,398
Effect of dilutive potential ordinary shares				
Effect of employee share bonus	27	43	68	49
Weighted-average number of ordinary shares (after adjustment of dilutive potential ordinary shares)	<u>38,425</u>	<u>38,441</u>	<u>38,466</u>	<u>38,447</u>
	<u>\$ 1.53</u>	<u>1.26</u>	<u>3.00</u>	<u>2.69</u>

(17) Revenue from contracts with customers

A. Disaggregation of revenue

	For the three months periods ended September 30		For the nine months periods ended September 30	
	2025	2024	2025	2024
Major products/service lines:				
Pharmaceuticals	\$ 252,295	234,923	738,215	607,797
Vaccine	152,808	137,662	190,949	138,838
Test	16,125	12,303	43,770	32,253
Services	1,355	3,644	6,063	45,725
	<u>\$ 422,583</u>	<u>388,532</u>	<u>978,997</u>	<u>824,613</u>

## B. Contract balances

	September 30, 2025	December 31, 2024	September 30, 2024
Notes receivable	\$ 11,218	11,048	11,405
Accounts receivable (included related parties)	351,523	203,168	323,889
Less: Allowance for expected credit losses	( 3,758)	( 2,533)	( 3,463)
Total	<b>\$ 358,983</b>	<b>211,683</b>	<b>331,831</b>
Contract liabilities	<b>\$ 1,864</b>	<b>1,039</b>	<b>3,436</b>

For details on notes receivable, accounts receivable and allowance for expected credit losses, please refer to note 6 (3).

The amount of revenue recognized for the nine months periods ended September 30, 2025 and 2024 that were included in the contract liability balance at the beginning of the period were \$1,039 thousand and \$1,034 thousand respectively.

### (18) Remuneration to employees and directors

On May 28, 2025, the shareholders' meeting resolved to amend the Articles of Incorporation. According to the amended provisions, if the Group has profits in a given fiscal year, 2% to 8% shall be allocated as employee compensation (among which, compensation to grassroots employees shall not be less than 0.05%), and up to 2% may be allocated as remuneration for directors and supervisors. However, if the Group has accumulated losses, such losses must be covered before any allocation is made. The recipients of employee compensation, whether in stock or cash, may include employees of subsidiaries who meet certain criteria. Under the previous version of the Articles, if the Group had profits in a given fiscal year, 2% to 8% was to be allocated as employee compensation, to be distributed in stock or cash as resolved by the board of directors. The recipients could include employees of controlling or subsidiary companies who met certain criteria. The Group could also allocate up to 2% of such profits as directors' remuneration, which could only be distributed in cash. The distribution plans for employee compensation and directors' remuneration were to be reported to the shareholders' meeting. However, if there were accumulated losses, such losses must first be covered before allocating employee compensation and directors' remuneration according to the aforementioned percentages.

For the three months and nine months periods ended September 30, 2025 and 2024, the Group estimated its employee compensation and directors' remuneration both amounting to \$1,394 thousand, \$1,126 thousand, \$3,082 thousand and \$2,585 thousand respectively. The estimated amounts mentioned above are calculated based on the net profit before tax, excluding the remuneration to employees and directors of each period, multiplied by the percentage of remuneration to employees, directors and supervisors as specified in the Group's articles of incorporation. These compensation and remunerations recognized as operating expenses during the period.

If there is a difference between the actual distribution amount and the estimated amount in the following year, it will be accounted for as an adjustment according to accounting estimates, and such difference will be recognized in the profit or loss for the following year. In the event that the board of directors decides to issue stock as employee compensation, the basis for calculating the number of shares for stock-based compensation is determined based on the closing price of common shares on the day before the board of directors' decision, taking into account any adjustments for dividends and rights issues.

For the fiscal year 2024, the Group accrued \$2,902 thousand as employee compensation and \$1,814 thousand as directors' remuneration. For the fiscal year 2023, both employee compensation and directors' remuneration were accrued at \$1,523 thousand. Related information is available on the Market Observation Post System website.

(19) Non-operating income and expenses

A. Interest income

The details of interest income were as follows:

	For the three months periods ended September 30		For the nine months periods ended September 30	
	2025	2024	2025	2024
Interest income from bank deposits	<u>\$ 1,243</u>	<u>542</u>	<u>5,602</u>	<u>2,934</u>

B. Other income

The details of other income were as follows:

	For the three months periods ended September 30		For the nine months periods ended September 30	
	2025	2024	2025	2024
Rent income	\$ 31	154	102	289
Other income-other	58	79	244	384
	<u>\$ 89</u>	<u>233</u>	<u>346</u>	<u>673</u>

C. Other gains and losses

The details of other gains and losses were as follows:

	For the three months periods ended September 30		For the nine months periods ended September 30	
	2025	2024	2025	2024
Foreign exchange gains (losses)	\$ 289	(153)	(59)	647
Dividends income	6,557	6,528	6,557	6,528
Gain on disposal of property, plant and equipment	-	(192)	-	(192)
Gain on disposal of investments	-	-	1,113	-
Others	(243)	(491)	(713)	(848)
Other gains and losses(net)	<u>\$ 6,603</u>	<u>5,692</u>	<u>6,898</u>	<u>6,135</u>

#### D. Finance costs

The details of finance costs were as follows:

	For the three months periods ended September 30		For the nine months periods ended September 30	
	2025	2024	2025	2024
Interest expenses – bank loan	\$ -	15	-	15
Interest expenses - lease liabilities	197	150	598	296
Interest expenses	<u>\$ 197</u>	<u>165</u>	<u>598</u>	<u>311</u>

#### (20) Financial instruments

Except as described below, there were no significant changes in the fair value of financial instruments and the exposure to credit risk, liquidity risk, and market risk arising from financial instruments of the Group. Please refer to Note 6(20) of the consolidated financial statements for 2024 for relevant information.

##### A. Credit risk

###### (A) Credit risk exposure

The carrying amount of financial assets represents the maximum amount exposed to credit risk.

###### (B) Concentration of credit risk

The Group has a customer base that includes hospitals, medical centers, pharmacies, and clinics, which results in the Group having no significant concentration of credit risk. The Group regularly assesses the likelihood of accounts receivable collection and recognize allowance for doubtful accounts, and the impairment losses are always within management's expectations.

###### (C) Credit risk of accounts receivables and debt securities

For credit risk exposure of notes and accounts receivables, please refer to note 6 (3).

Other financial assets at amortized cost includes other receivables and time deposits. All of these financial assets are considered to have low risk, and thus, the impairment provision recognized during the period was limited to 12 months expected losses. Regarding how the financial instruments are considered to have low credit risk, please refer to note 4 (7). There were no recognition and reversal of impairment losses for the nine months periods ended September 30, 2025 and 2024. The balance as of September 30, 2025 and 2024 are both zero.

##### B. Liquidity risk

The following table shows the contractual maturities of financial liabilities, including estimated interest payments.

	<b>Carrying amount</b>	<b>Contractual cash flows</b>	<b>Within a year</b>	<b>2~3 years</b>	<b>4~5 years</b>
<b>September 30, 2025</b>					
Non-derivative financial liabilities					
Notes and accounts payable (including related parties)	\$ 176,836	176,836	176,836	-	-
Other payables	95,954	95,954	95,954	-	-
Lease liabilities	18,911	19,777	11,428	8,349	-
	<b>\$ 291,701</b>	<b>292,567</b>	<b>284,218</b>	<b>8,349</b>	<b>-</b>

<b>December 31, 2024</b>					
Non-derivative financial liabilities					
Notes and accounts payable (including related parties)	\$ 71,355	71,355	71,355	-	-
Other payables	90,708	90,708	90,708	-	-
Lease liabilities	20,431	21,291	10,646	10,407	238
	<b>\$ 182,494</b>	<b>183,354</b>	<b>172,709</b>	<b>10,407</b>	<b>238</b>

<b>September 30, 2024</b>					
Non-derivative financial liabilities					
Notes and accounts payable (including related parties)	\$ 147,175	147,175	147,175	-	-
Other payables	88,353	88,353	88,353	-	-
Lease liabilities	12,758	13,464	7,870	5,070	524
	<b>\$ 248,286</b>	<b>248,992</b>	<b>243,398</b>	<b>5,070</b>	<b>524</b>

The Group does not expect the cash flows included in the maturity analysis to occur significantly earlier or at significantly different amounts.

## C. Currency risk

### (A) Exposure to foreign currency risk

The Group's significant exposure to foreign currency risk were as follows:

The Group's significant exposure to foreign currency risk were as follows:										
	September 30, 2025				December 31, 2024			September 30, 2024		
	Foreign currency	Exchange rate	TWD		Foreign currency	Exchange rate	TWD	Foreign currency	Exchange rate	TWD
Financial assets										
Monetary items										
USD	\$	243	30.445	7,384	169	32.785	5,554	164	31.65	5,188
HKD		343	3.913	1,342	342	4.222	1,445	341	4.075	1,390

### (B) Sensitivity analysis

The Group's exposure to foreign currency risk arises from the translation of the foreign currency exchange gains and losses on cash and cash equivalents that is denominated in foreign currency. A strengthening (weakening) 1% of the TWD against the USD, CNY, and HKD as of September 30, 2025 and 2024 would have decreased the net profit after tax by \$70 and \$53 thousand, respectively. The analysis assumes that all other variables remain constant and ignores any impact of forecasted sales and purchases. The analysis is performed on the same basis for both periods.

(C) Foreign exchange gain and loss on monetary items

Due to the variety of functional currencies in the Group, exchange gain or loss information on monetary items is disclosed on an aggregated basis. For the three months periods ended September 30 in 2025 and 2024, as well as for the nine months ended September 30 in 2025 and 2024, the foreign exchange gains and losses (including both realized and unrealized) were gains of \$289, losses of \$153, losses of \$59, and gains of \$647, respectively.

(D) Interest rate risk : None.

(E) Other market price risk

For the nine months periods ended September 30, 2025 and 2024, the sensitivity analysis for the changes in the securities price at the reporting date were performed using the same basis for the profit and loss with all other variable factors remaining constant as illustrated below:

Prices of securities at the reporting date	For the nine months periods ended September 30,			
	2025		2024	
	Other comprehensive income after tax	Net income	Other comprehensive income after tax	Net income
Increasing 10%	\$ 27,921	-	28,132	-
Decreasing 10%	(\$ 27,921)	-	(28,132)	-

D. Fair value of financial instruments

(A) Categories of financial instruments and fair value hierarchy

The fair value of financial assets at fair value through other comprehensive income is measured on a recurring basis. The carrying amount and fair value of the Group's financial assets and liabilities, including the information on fair value hierarchy, were as follows; however, except as described in the following paragraphs, for financial instruments not measured at fair value whose carrying amount is reasonably close to the fair value, and lease liabilities, disclosure of fair value information is not required:

	September 30, 2025				
	Book Value	Fair Value			Total
		Level 1	Level 2	Level 3	
Financial assets at fair value through other comprehensive income					
Domestic listed stocks	\$ 179,850	179,850	-	-	179,850
Domestic OTC stocks	88,876	88,876	-	-	88,876
Foreign unlisted stocks	10,479	-	-	10,479	10,479
Subtotal	279,205	268,726	-	10,479	279,205
Financial assets measured at amortized cost					
Cash and cash equivalents	\$ 588,644	-	-	-	-
Notes and accounts receivable (including related parties)	358,983	-	-	-	-
Other receivables	2,991	-	-	-	-
Other financial assets	237,000	-	-	-	-
Refundable deposits	8,026	-	-	-	-
Subtotal	1,195,644	-	-	-	-
Total	\$ 1,474,849	268,726	-	10,479	279,205

September 30, 2025					
	Book Value	Fair Value			Total
		Level 1	Level 2	Level 3	
Financial liabilities at amortized cost					
Notes and accounts payable (including related parties)	\$ 176,836	-	-	-	-
Other payables (including related parties)	95,954	-	-	-	-
Lease liabilities	18,911	-	-	-	-
Total	<u>\$ 291,701</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
December 31, 2024					
	Book Value	Fair Value			Total
		Level 1	Level 2	Level 3	
Financial assets at fair value through other comprehensive income					
Domestic listed stocks	\$ 175,734	175,734	-	-	175,734
Domestic OTC stocks	77,015	77,015	-	-	77,015
Foreign unlisted stocks	10,479	-	-	10,479	10,479
Subtotal	<u>263,228</u>	<u>252,749</u>	<u>-</u>	<u>10,479</u>	<u>263,228</u>
Financial assets measured at amortized cost					
Cash and cash equivalents	\$ 588,342	-	-	-	-
Notes and accounts receivable (including related parties)	211,683	-	-	-	-
Other receivables	2,182	-	-	-	-
Other financial assets	232,000	-	-	-	-
Refundable deposits	8,750	-	-	-	-
Subtotal	<u>1,042,957</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Total	<u>\$ 1,306,185</u>	<u>252,749</u>	<u>-</u>	<u>10,479</u>	<u>263,228</u>
Financial liabilities at amortized cost					
Notes and accounts payable (including related parties)	\$ 71,335	-	-	-	-
Other payables(including related parties)	90,708	-	-	-	-
Lease liabilities	20,431	-	-	-	-
Total	<u>\$ 182,494</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
September 30, 2024					
	Book Value	Fair Value			Total
		Level 1	Level 2	Level 3	
Financial assets at fair value through other comprehensive income					
Domestic listed stocks	\$ 173,992	173,992	-	-	173,992
Domestic OTC stocks	98,307	98,307	-	-	98,307
Foreign unlisted stocks	9,017	-	-	9,017	9,017
Subtotal	<u>281,316</u>	<u>272,299</u>	<u>-</u>	<u>9,017</u>	<u>281,316</u>

September 30, 2024					
		Fair Value			
	Book Value	Level 1	Level 2	Level 3	Total
Financial assets measured at amortized cost					
Cash and cash equivalents	\$ 585,106	-	-	-	-
Notes and accounts receivable (including related parties)	331,831	-	-	-	-
Other receivables	37,718	-	-	-	-
Other financial assets	127,000	-	-	-	-
Refundable deposits	9,107	-	-	-	-
Subtotal	1,090,762	-	-	-	-
Total	\$ 1,372,078	272,299	-	9,017	281,316
Financial liabilities at amortized cost					
Notes and accounts payable (including related parties)	\$ 147,175	-	-	-	-
Other payables (including related parties)	88,353	-	-	-	-
Lease liabilities	12,758	-	-	-	-
Total	\$ 248,286	-	-	-	-

(B) Fair value hierarchy

The table below analyzes financial instruments carried at fair value by the levels in the fair value hierarchy. The different levels have been defined as follows:

- Level 1: quoted prices (unadjusted) in active markets for identified assets or liabilities.
- Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

(C) Valuation techniques for financial instruments not measured at fair value

The Group estimates its financial instruments, that are not measured at fair value, by methods and assumption as follows:

Cash and cash equivalents, accounts receivables, other financial assets, notes payable and accounts payable are either close to their expiry date, or their future receivable or payable are close to their carrying value; thus, their fair value are estimated from the book value of the balance sheet date.

(D) Valuation techniques for financial instruments measured at fair value

(D.1) Non-derivative financial instruments

Financial instruments traded in active markets are based on quoted market prices. The quoted price of a financial instrument obtained from main exchanges and on-the-run bonds from Taipei Exchange can be used as a basis to determine the fair value of the listed companies' equity instrument and debt instrument of the quoted price in an active market.

If a quoted price of a financial instrument can be obtained in time and often from exchanges, brokers, underwriters, industrial union, pricing institute, or authorities, and such price can reflect those actual trading and frequently happen in the market, then the financial instrument is considered to have a quoted price in an active market. If a financial instrument is not in accordance with the definition mentioned above, then it is considered to be without a quoted

price in an active market. In general, market with low trading volume or high bid-ask spreads is an indication of a non-active market.

The fair value of the financial instruments held by the Group are determined by reference to the market quotation.

If the financial instruments held by the Group have no active market, their fair values are listed as follows according to their categories and attributes:

- Equity instruments without public quotation: The fair value is measured by using the transaction prices of the stocks of companies engaged in the same or similar businesses in the active market, the value multipliers implied by these prices, and related transaction information to determine the value of the financial instruments, as well as adjusted for considering liquidity discount.

(E) Transfer between levels

There was no change in valuation techniques for financial instruments measured at fair value for the nine months periods ended September 30, 2025 and 2024, so there was no transfer between levels.

(F) Reconciliation of level 3 fair values:

	<b>Fair value through other comprehensive income Equity instruments without quoted price</b>
Balance as of January 1, 2025	\$ 10,479
Balance as of September 30, 2025	<b>\$ 10,479</b>
Balance as of January 1, 2024	\$ 9,017
Balance as of September 30, 2024	<b>\$ 9,017</b>

(G) Quantified information on significant unobservable inputs (Level 3) used in fair value measurement

The Group's financial instruments that use Level 3 inputs to measure fair value include financial assets at fair value through other comprehensive income - equity investments.

The majority of fair values of the Group are classified as Level 3, with only a single significant unobservable input, while equity investments without active market are characterized by multiple significant unobservable inputs. The significant unobservable inputs of the equity investments without an active market are individually, and there is no correlation between them.

Quantified information of significant unobservable inputs was as follows:

Item	Valuation technique	Significant unobservable inputs	Inter-relationship between significant unobservable inputs and fair value measurement
Financial assets at fair value through other comprehensive income — equity investments without an active market	Comparable companies method	Discount for lack of market liquidity (as of September 30, 2025, December 31, 2024 and September 30, 2024, the rate were all 30%)	The estimated fair value would decrease if the discount for lack of market liquidity was higher.

(H) Fair value measurements in Level 3 – sensitivity analysis of reasonably possible alternative assumptions

The Group's measurement on the fair value of financial instruments is deemed reasonable. However, use of different valuation models or assumptions may lead to different results. The following is the effect on other comprehensive income from financial assets categorized within Level 3 if the inputs used to valuation models have changed:

			Recognized in other comprehensive income	
	Input value	Degree of variation	Favourable change	Unfavourable change
September 30, 2025				
Financial assets at fair value through other comprehensive income				
Equity investments without an active market	Market liquidity discount rate	1%	105 (	105)
December 31, 2024				
Financial assets at fair value through other comprehensive income				
Equity investments without an active market	Market liquidity discount rate	1%	105 (	105)
September 30, 2024				
Financial assets at fair value through other comprehensive income				
Equity investments without an active market	Market liquidity discount rate	1%	90 (	90)

The favorable and unfavorable effects represent the changes in fair value, and fair value is based on a variety of unobservable inputs calculated using a valuation technique. The analysis above only reflects the effects of changes in a single input, and it does not include the interrelationships with another input.

(21) Financial risk management

There have been no significant changes to the financial risk management objectives and policies of the Group as disclosed in Note 6(21) of the financial statements for the year ended December 31, 2024.

(22) Capital management

The capital management objectives, policies, and procedures of the consolidated company remain consistent with those disclosed in the consolidated financial statements for the year ended December 31, 2024. Additionally, there have been no significant changes to the aggregated quantitative data for items related to capital management as disclosed in the consolidated financial statements for the year ended December 31, 2024. Please refer to Note 6(22) of the consolidated financial statements for the year ended December 31, 2024 for relevant information.

(23) Investing and financing activities not affecting current cash flow

The Group's investing and financing activities which did not affect the current cash flow for the nine months periods ended September 30, 2025 and 2024, were as follows:

A. Acquisition of right-of-use assets under leases, please refer to note 6(8).

B. Reconciliation of liabilities arising from financing activities were as follows:

	January 1, 2025	Cash flow	Non-cash changes Others	September 30, 2025
Lease liabilities	<u>\$ 20,431</u>	<u>( 9,171)</u>	<u>7,651</u>	<u>18,911</u>

	January 1, 2024	Cash flow	Non-cash changes Others	September 30, 2024
Lease liabilities	<u>\$ 7,397</u>	<u>( 9,174)</u>	<u>14,535</u>	<u>12,758</u>

## 7. Related-party transactions

(1) Parent company and ultimate controlling company

TTY Biopharm Company Limited is both the parent company and the ultimate controlling party of the Group. It owns 56.48% of all shares outstanding of the Group, and has issued the consolidated financial statements available for public use.

(2) Names and relationship with related parties

The followings are entities that have transactions with related party during the periods covered in the financial statements.

Name of related parties	Relationship with the Group
TTY Biopharm Company Limited	Parent company
American Taiwan Biopharm(Thailand)	Other related party

(3) Significant related-party transactions

A. Operating revenue

The amounts of significant sales by the Group to its related parties were as follows:

	For the three months periods ended September 30		For the nine months periods ended September 30	
	2025	2024	2025	2024
Parent company- TTY Biopharm Company Limited	\$ 2,584	3,645	9,614	5,726
Other related parties	-	2,268	4,683	4,448
	<u>\$ 2,584</u>	<u>5,913</u>	<u>14,297</u>	<u>10,174</u>

The selling price and payment terms to related parties were not significantly different from those of sales to third parties. The collection terms for sales to related parties were month-end 60-90 days,

or 14 days after the date of shipment. The collection terms for commission were month-end 30 and 90 days.

#### B. Purchases

The amounts of significant purchases by the Group from related parties were as follows:

	For the three months periods ended September 30		For the nine months periods ended September 30	
	2025	2024	2025	2024
Parent company - TTY Biopharm Company Limited	<u>\$ 148,056</u>	<u>123,406</u>	<u>246,566</u>	<u>204,753</u>

The pricing and payment terms with related parties were not materially different from those of purchases with third parties. The payment terms for purchases from related parties were month-end 30-90 days.

#### C. Receivables from related parties

The amounts of receivables from related parties were as follows:

Items	Related Party Categories	September 30, 2025	December 31, 2024	September 30, 2024
Accounts receivable	Parent company	<u>\$ 1,138</u>	<u>1,177</u>	<u>3,534</u>

#### D. Payables to related parties

The amounts of payables to related parties were as follows:

Items	Related Party Categories	September 30, 2025	December 31, 2024	September 30, 2024
Accounts payable	Parent company - TTY	\$ 144,510	36,766	115,932
Other payables	Parent company	1,883	1,918	2,322
		<u>\$ 146,393</u>	<u>38,684</u>	<u>118,254</u>

#### E. Lease

The Group leases offices and equipments from the parent company, and the details were as follows:

Items	September 30, 2025	December 31, 2024	September 30, 2024
Guarantee deposits paid	<u>\$ 838</u>	<u>838</u>	<u>788</u>
Lease liabilities	<u>\$ 6,213</u>	<u>9,875</u>	<u>1,179</u>

  

	For the three months periods ended September 30		For the nine months periods ended September 30	
	2025	2024	2025	2024
Interest paid	<u>\$ 31</u>	<u>8</u>	<u>110</u>	<u>38</u>

## F. Others

The operating expenses paid by the Group to the parent company due to the operating and business transactions were as follows:

Items	For the three months periods ended September 30		For the nine months periods ended September 30	
	2025	2024	2025	2024
Operating expenses	<u>\$ 1,607</u>	<u>1,683</u>	<u>4,750</u>	<u>4,940</u>

## (4) Key management personnel compensation

	For the three months periods ended September 30		For the nine months periods ended September 30	
	2025	2024	2025	2024
Short-term employee benefits	\$ 12,871	10,630	34,936	32,724
Post-employment benefits	<u>293</u>	<u>307</u>	<u>838</u>	<u>944</u>
	<u>\$ 13,164</u>	<u>10,937</u>	<u>35,774</u>	<u>33,668</u>

## 8. Pledged assets:

The details of the book value of assets pledged as collateral by the Group are as follows:

Items	Pledged Collateral	September 30, 2025	December 31, 2024	September 30, 2024
Other financial assets-non current	Agency distribution payment	<u>\$ 10,000</u>	<u>5,000</u>	<u>-</u>

## 9. Significant commitments and contingencies

As of September 30, 2025, December 31, 2024 and September 30, 2024, the unrecognized contractual commitments of the Group were as follows:

	September 30, 2025	December 31, 2024	September 30, 2024
Contract with other units for research and development	<u>\$ 18,587</u>	<u>19,099</u>	<u>20,233</u>
Acquisition of intangible assets	<u>\$ 7,257</u>	<u>4,286</u>	<u>4,458</u>

## 10. Losses due to major disasters: None.

## 11. Subsequent events: None.

## 12. Others

(1) The followings are the summary of employee benefits, depreciation, and amortization by function :

By function By item	For the three months periods ended September 30, 2025			For the three months periods ended September 30, 2024		
	Operating cost	Operating expenses	Total	Operating cost	Operating expenses	Total
Employee benefits						
Salary	1,818	54,269	56,087	2,728	52,883	55,611
Labor and health insurance	175	4,002	4,177	119	3,522	3,641
Pension	91	2,343	2,434	59	2,741	2,800
Others	99	2,005	2,104	50	2,231	2,281
Depreciation	806	3,383	4,189	580	4,696	5,276
Amortization	-	2,622	2,622	-	2,699	2,699

By function By item	For the nine months periods ended September 30, 2025			For the nine months periods ended September 30, 2024		
	Operating cost	Operating expenses	Total	Operating cost	Operating expenses	Total
Employee benefits						
Salary	6,148	160,893	167,041	2,728	140,341	143,069
Labor and health insurance	551	12,288	12,839	119	10,841	10,960
Pension	280	7,209	7,489	59	6,829	6,888
Others	224	5,479	5,703	50	4,786	4,836
Depreciation	2,373	10,100	12,473	1,133	12,622	13,755
Amortization	-	7,476	7,476	-	7,990	7,990

(2) Others:

The Group donated \$7,722, \$3,536, \$13,834 and \$9,452 to related medical foundation and associations to support non-profit organizations developing drugs, promoting disease prevention and correct dosages for the three months and nine months ended September 30, 2025 and 2024, respectively.

(3) Seasonality of operations

The operations of the Group are not affected by seasonal or cyclical factors.

## 13. Other disclosures

(1) Information on significant transactions

The following is the information on significant transactions required by the “Regulations Governing the Preparation of Financial Reports by Securities Issuers” for the Group

A. Loans to other parties: None.

B. Guarantees and endorsements for other parties: None.

C. Securities held as of September 30, 2025 (excluding those investments in subsidiaries, associates and joint ventures):

(In Thousands of New Taiwan Dollars/Thousands shares)

Name of holder	Category and name of security	Relationship with Group	Account title	Ending balance				Note
				Shares/Units (thousands)	Carrying value	Percentage of ownership (%)	Fair value	
TSH Biopharm Corporation Ltd.	Lumosa Therapeutics Co., Ltd.	-	Current financial assets at fair value through other comprehensive income	308	88,876	0.18 %	88,876	
"	Fubon Financial Holding Co., Ltd. Preferred stock B	-	Non-current financial assets at fair value through other comprehensive income	2,500	155,000	0.38 %	155,000	
"	Union Bank of Taiwan Preferred stock A	-	"	400	21,720	0.20 %	21,720	
	Fubon Financial Holding Co., Ltd. Preferred stock C	-	"	58	3,130	0.02%	3,130	
"	CellMax Ltd.	-	"	1,593	10,479	- %	10,479	

D. Related-party transactions for purchases and sales with amounts exceeding the lower of NT\$100 million or 20% of the capital stock:

(In Thousands of New Taiwan Dollars/Thousands shares)

Purchaser /seller	Counterparty	Relationship with the counterparty	Transaction				Differences in transaction term compared to third party transactions		Notes/accounts receivable (payable)		Footnote
			Purchases (sales)	Amount	Percentage of total purchases (sales)	Credit term	Unit price	Credit term	Balance	Percentage of total notes/accounts receivable (payable)	
Chuang Yi Biotech Co. Ltd.	TTY Biopharm Company Limited	Ultimate parent company	Purchases	186,299	95.78%	month-end 90 days	Normal	Not significantly different from general manufacturers.	(138,721)	(99.51)%	

E. Receivables from related parties with amounts exceeding the lower of NT\$100 million or 20% of the capital stock: None.

F. Business relationships and significant intercompany transactions:

Number	Trader's name	Counterparty	Relationship with the trader	Transaction details			
				Account title	Amount	Transaction conditions	Ratio of combined total revenue or total assets
0	TSH Biopharm Corporation Ltd.	Top Pharma Medical-wares Co., Ltd.	1	Sales revenue	64,227	According to the contract terms	6.56%
0	TSH Biopharm Corporation Ltd.	Top Pharma Medical-wares Co., Ltd.	1	Notes receivable	10,064	"	0.50%
0	TSH Biopharm Corporation Ltd.	Top Pharma Medical-wares Co., Ltd.	1	Accounts receivable	6,362	"	0.32%
0	TSH Biopharm Corporation Ltd.	Top Pharma Medical-wares Co., Ltd.	1	Other receivables	5,111	"	0.25%

Note 1、The numbering format is as follows：

- 0 Representing the parent company.
- Subsidiaries numbered sequentially starting from Arabic numeral 1.

Note 2、Types of relationships with the trader are indicated as follows:

- Parent company to subsidiary.
- Subsidiary to parent company
- Subsidiary to subsidiary

Note 3、When preparing consolidated financial statements, all amounts have been fully offset.

Note 4、Individual amounts not exceeding \$1,000 thousand will not be disclosed, and their corresponding transactions will no longer be disclosed.

(2) Information on investees:

(In Thousands of New Taiwan Dollars/Thousands shares)

Investor Company	Investee Company	Location	Main Businesses and Products	Original Investment Amount		Balance as of September 30, 2025			Net Income (losses) of the investee	The amount of investment gain or loss recognized in the current period.	Footnote
				September 30, 2025	December 31, 2024	Shares	Percentage of Ownership	Carrying Value			
TSH Biopharm Corporation Ltd.	Chuang Yi Biotech Co. Ltd.	Taiwan	Selling of health food	200,262	200,262	16,590	51.60%	190,131	38,981	20,114	
TSH Biopharm Corporation Ltd.	Top Pharma Medical-wares Co., Ltd.	Taiwan	Selling of medicine and dietary supplement	301,451	257,121	3,794	51.00%	330,341	28,570	14,571	
TSH Biopharm Corporation Ltd.	TOP Biological Technology Company Limited.	Taiwan	Food manufacturing industry	-	44,330	-	- %	-	-	-	
Chuang Yi Biotech Co. Ltd.	Immortal Fame Global Ltd.	SAMOA	General export trade and investment in various production enterprises	-	16,820	-	- %	-	-	-	

Note 1 : The aforementioned transactions were eliminated in the preparation of consolidated financial statements.

Note 2 : For changes in subsidiaries included in the consolidated financial statements, please refer to Note 4(2).

(3) Information on investment in mainland China : None.

## 14. Segment information

### (1) General information

The Group's operating segments required to be disclosed are categorized as Domestic Cardiovascular Business Unit, Gastrointestinal Drugs Business Unit, and Investment Business Unit, etc.

The segments' profit is measured at profit before tax. The Group assesses performance of the segments based on the segments' profit. The operating segments' accounting policies are similar to those described in Note 4 "significant accounting policies"

### (2) Information about reportable segments and their measurement and reconciliations

The Group's operating segment information and reconciliation are as follows:

For the 3 months ended September 30, 2025	Domestic Cardiovascular and Gastrointestinal Drugs	Investment	Adjustment and elimination	Total
Revenue				
Revenue from external customer	\$ 149,618	272,965	-	422,583
Interest revenue	22,480	9	(22,489)	-
Total	<u>\$ 172,098</u>	<u>272,974</u>	<u>(22,489)</u>	<u>422,583</u>

**Reportable segment profit or**

loss	\$	<u>42,727</u>	<u>49,259</u>	-	<u>91,986</u>
------	----	---------------	---------------	---	---------------

<u>For the 3 months ended September 30, 2024</u>	<u>Domestic Cardiovascular and Gastrointestinal Drugs</u>	<u>Investment</u>	<u>Adjustment and elimination</u>	<u>Total</u>
Revenue				
Revenue from external customer	\$ 127,491	261,041	-	388,532
Interest revenue	20,706	684	(21,390)	-
Total	<u>\$ 148,197</u>	<u>261,725</u>	<u>(21,390)</u>	<u>388,532</u>

**Reportable segment profit or**

loss	\$	<u>29,773</u>	<u>50,308</u>	-	<u>80,081</u>
------	----	---------------	---------------	---	---------------

<u>For the 9 months ended September 30, 2025</u>	<u>Domestic Cardiovascular and Gastrointestinal Drugs</u>	<u>Investment</u>	<u>Adjustment and elimination</u>	<u>Total</u>
Revenue				
Revenue from external customer	\$ 437,683	541,314	-	978,997
Interest revenue	64,227	42	(64,269)	-
Total	<u>\$ 501,910</u>	<u>541,356</u>	<u>(64,269)</u>	<u>978,997</u>
Reportable segment profit or loss	<u>\$ 111,022</u>	<u>77,068</u>	<u>-</u>	<u>188,090</u>

**For the 9 months ended  
September 30, 2024**

Revenue				
Revenue from external customer	\$ 427,053	397,560	-	824,613
Interest revenue	42,940	705	(43,645)	-
Total	<u>\$ 469,993</u>	<u>398,265</u>	<u>(43,645)</u>	<u>824,613</u>
Reportable segment profit or loss	<u>\$ 104,229</u>	<u>47,090</u>	<u>-</u>	<u>151,319</u>

**Reportable segment assets**

30-Sep-25	\$	<u>1,518,568</u>	<u>1,021,111</u>	<u>(520,472)</u>	<u>2,019,207</u>
31-Dec-24	\$	<u>1,483,408</u>	<u>850,186</u>	<u>(491,401)</u>	<u>1,842,193</u>
30-Sep-24	\$	<u>1,468,622</u>	<u>925,053</u>	<u>(488,286)</u>	<u>1,905,389</u>